Artikel
Delayed cell injection of allogenic mesenchymal progenitor cells for bone regeneration in an ovine critical-sized segmental tibial bone defect
Suche in Medline nach
Autoren
-
Arne Berner
- Klinik für Unfallchirurgie, Klinikum der Universität Regensburg, Regensburg, Germany
-
Jan Henkel
- Institute of Health and Biomedical Innovations, Queensland University of Technology, Kelvin Grove, Australia
-
Maria Ann Woodruff
- Institute of Health and Biomedical Innovations, Queensland University of Technology, Kelvin Grove, Australia
-
Michael Schütz
- Institute of Health and Biomedical Innovations, Queensland University of Technology, Kelvin Grove, Australia
-
Michael Nerlich
- Klinik für Unfallchirurgie, Klinikum der Universität Regensburg, Regensburg, Germany
-
Dietmar Werner Hutmacher
- Institute of Health and Biomedical Innovations, Queensland University of Technology, Kelvin Grove, Australia
| Veröffentlicht: | 5. Oktober 2015 |
|---|
Gliederung
Text
Objectives: Mesenchymal progenitor cells (MPCs) represent an attractive cell population for the concept of bone tissue engineering. Their special immunological characteristics suggest that MPCs can be used in an allogenic application. The results using the current cell-based concepts are discussed controversially. This might be due to the high rate of cell death caused by local hypoxia and low nutrition supply in large bone defects. Therefore, we present in our study a novel technique of delayed cell delivery for large bone defect regeneration, to improve the outcome of cell transplantation for bone regeneration.
Methods: A 3cm segmental tibial bone defect was created in 18 adult merino sheep (aged 6-7 years). Ovine MPCs were isolated from bone marrow aspirates, expanded and cultured with osteogenic media for two weeks before implantation. 4 weeks after the implantation of the scaffolds, the cells (100 x 106 allogenic MPCs) were injected percutaneous into a mPCL/TCP scaffold (n=6). Bone healing was assessed after 12 month post surgery by radiology, micro computed tomography and biomechanical testing.
Results and Conclusion: Delayed injection of allogenic cells did not lead to a local or systemic rejection. Radiology, microCT, biomechanical testing and histology showed significant more bone formation in the cell groups compared to the empty scaffold group.
Delayed allogenic cell transplantation of mesenchymal progenitor cells leads to higher bone regeneration compared to the control group. This novel procedure of cell delivery could overcome the current problems of cell-based tissue engineering and serve as a baseline for the translation of novel concepts into clinical application.
